Readystate Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Readystate Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,749	Closed	-$444K	–	614
2024 Q4	$444K	Buy	6,749 +1,495	+28%	+$100K	0.01%	505
2024 Q3	$369K	Sell	5,254 -5,657	-52%	-$473K	0.01%	497
2024 Q2	$898K	Sell	10,911 -1,815	-14%	-$151K	0.03%	342
2024 Q1	$1.11M	Hold	12,726	–	–	0.02%	678
2023 Q4	$1.23M	Sell	12,726 -3,674	-22%	-$325K	0.04%	370
2023 Q3	$1.45M	Buy	+16,400	New	+$1.46M	0.07%	275
2023 Q1	–	Sell	-8,419	Closed	-$871K	–	332
2022 Q4	$871K	Buy	+8,419	New	+$790K	0.21%	61

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Readystate Asset Management's BMRN Position: Q1 2025 in Review

Readystate Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 6,749 shares — an estimated $444K sold.

Readystate Asset Management first reported a position in BMRN in Q4 2022 and held it in 7 quarters. The position peaked at $1.45M in Q3 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Readystate Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Readystate Asset Management sold 6,749 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $444K.
Readystate Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Readystate Asset Management's BioMarin Pharmaceuticals position peaked at $1.45M in Q3 2023.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Readystate Asset Management's 13F filing for Q1 2025, filed 6 May 2025.